Taejoon Pharmaceutical succeeds in avoiding the patent for Novartis’s glaucoma treatment ‘Simbrinza eyedrops (brimonidine+ brinzolamide).’

Being the only company to successfully avoid Novartis’s patent, Taejoon Pharmaceutical will now be able to develop a generic version of Simbrinza Eye Drops in a relatively relaxed manner.

According to industry sources on the 30th, Taejoon Pharmaceutical recently won the Passive Trial to Confirm the Scope of Patent Rights it filed against the composition patent of Novartis’ Simbrinza Eye Drops.

Taejoon Pharmaceutical had filed the suit in July last year, and this is the only patent registered in Korea for Simbrinza Eye Drops